School of Medicine, University of California, San Francisco, San Francisco, California.
Department of Surgery, University of California, San Francisco, San Francisco, California.
Am J Transplant. 2019 Dec;19(12):3308-3318. doi: 10.1111/ajt.15552. Epub 2019 Sep 3.
The Pediatric End-Stage Liver Disease (PELD) score is intended to determine priority for children awaiting liver transplantation. This study examines the impact of PELD's incorporation of "growth failure" as a threshold variable, defined as having weight or height <2 standard deviations below the age and gender norm (z-score <2). First, we demonstrate the "growth failure gap" created by PELD's current calculation methods, in which children have z-scores <2 but do not meet PELD's growth failure criteria and thus lose 6-7 PELD points. Second, we utilized United Network for Organ Sharing (UNOS) data to investigate the impact of this "growth failure gap." Among 3291 pediatric liver transplant candidates, 26% met PELD-defined growth failure, and 17% fell in the growth failure gap. Children in the growth failure gap had a higher risk of waitlist mortality than those without growth failure (adjusted subhazard ratio [SHR] 1.78, 95% confidence interval [95% CI] 1.05-3.02, P = .03). They also had a higher risk of posttransplant mortality (adjusted HR 1.55, 95% CI 1.03-2.32, P = .03). For children without PELD exception points (n = 1291), waitlist mortality risk nearly tripled for those in the gap (SHR 2.89, 95% CI 1.39-6.01, P = .005). Current methods for determining growth failure in PELD disadvantage candidates arbitrarily and increase their waitlist mortality risk. PELD should be revised to correct this disparity.
小儿终末期肝病 (PELD) 评分旨在确定等待肝移植的儿童的优先级。本研究探讨了 PELD 将“生长发育迟缓”作为一个阈值变量纳入其中的影响,其定义为体重或身高低于年龄和性别标准的 2 个标准差(z 评分 <2)。首先,我们展示了 PELD 当前计算方法造成的“生长发育迟缓差距”,其中儿童的 z 评分 <2,但不符合 PELD 的生长发育迟缓标准,因此失去 6-7 个 PELD 分数。其次,我们利用器官共享联合网络 (UNOS) 数据研究了这种“生长发育迟缓差距”的影响。在 3291 名小儿肝移植候选者中,26%符合 PELD 定义的生长发育迟缓,17%处于生长发育迟缓差距中。生长发育迟缓差距中的儿童等待名单死亡率高于无生长发育迟缓的儿童(调整后的亚危险比 [SHR] 1.78,95%置信区间 [95%CI] 1.05-3.02,P = 0.03)。他们也有更高的移植后死亡率风险(调整后的 HR 1.55,95%CI 1.03-2.32,P = 0.03)。对于没有 PELD 例外分数的儿童(n = 1291),处于差距中的儿童的等待名单死亡率风险几乎增加了两倍(SHR 2.89,95%CI 1.39-6.01,P = 0.005)。PELD 中确定生长发育迟缓的当前方法对候选者不利,增加了他们的等待名单死亡率风险。PELD 应进行修订以纠正这种差距。